Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsWhen it comes to treating metastatic hormone-sensitive prostate cancer, androgen receptor pathway inhibitors (ARPIs) beat docetaxel — but choosing between them may come down to cost and side effects. A large real-world study found abiraterone, apalutamide, and enzalutamide all significantly extended progression-free survival compared to docetaxel when combined with androgen-deprivation therapy, with no meaningful differences among the three ARPIs.
A new real-world study offers some of the most comprehensive comparative data yet on treatment options for metastatic hormone-sensitive prostate cancer (mHSPC). Analyzing over 9,000 men from a large US claims database, researchers found that all three ARPI doublets — abiraterone, apalutamide, and enzalutamide, each paired with androgen-deprivation therapy (ADT) — significantly outperformed docetaxel plus ADT in progression-free survival. Importantly, no meaningful differences were found among the three ARPIs themselves.
Since no head-to-head randomized trials exist comparing these drugs directly, the findings fill a notable evidence gap. The authors suggest that when survival outcomes are similar, treatment decisions should hinge on practical factors like cost, tolerability, and individual patient needs.
By the Numbers:
Why it matters: With multiple ARPI options available and no randomized trials comparing them head-to-head, clinicians have lacked clear guidance. This study provides real-world evidence to support individualized treatment decisions based on cost, side effects, and patient preferences rather than efficacy differences alone.
